{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:54:03Z","timestamp":1792198443363,"version":"4.4.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,2,14]],"date-time":"2021-02-14T00:00:00Z","timestamp":1613260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,14]],"date-time":"2021-02-14T00:00:00Z","timestamp":1613260800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Colorectal Dis"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s00384-021-03888-9","type":"journal-article","created":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T01:24:57Z","timestamp":1613611497000},"page":"1311-1319","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["The comparison of FOLFOX regimens with different doses of 5-FU for the adjuvant treatment of colorectal cancer: a multicenter study"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4597-9721","authenticated-orcid":false,"given":"Nadiye","family":"Akdeniz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammet Ali","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Do\u011fan","family":"Uncu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mevl\u00fcde","family":"\u0130nan\u00e7","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serap","family":"Kaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faysal","family":"Dane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"K\u00fc\u00e7\u00fck\u00f6ner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ay\u015fe","family":"Demirci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Bilici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ay\u015fe G\u00f6k","family":"Durnal\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lokman","family":"Koral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Ali Nahit","family":"\u015eendur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cihan","family":"Erol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esma","family":"T\u00fcrkmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6mer Fatih","family":"\u00d6lmez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zg\u00fcr","family":"A\u00e7\u0131kg\u00f6z","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u015eahin","family":"La\u00e7in","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayriye","family":"\u015eahinli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuhat","family":"Urak\u00e7\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdurrahman","family":"I\u015f\u0131kdo\u011fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,14]]},"reference":[{"key":"3888_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"7","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A (2020) Cancer statistics 2020. CA Cancer J for Clin 7:7\u201330","journal-title":"CA Cancer J for Clin"},{"key":"3888_CR2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40880-019-0377-5","volume":"39","author":"C Fortea-Sanchis","year":"2019","unstructured":"Fortea-Sanchis C, Forcadell-Comes E, Martinez-Ramos D et al (2019) Modelling the probability of erroneous negative lymph node staging in patients with colon cancer. Cancer Commun 39:31","journal-title":"Cancer Commun"},{"key":"3888_CR3","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1093\/jnci\/djh275","volume":"96","author":"JB O\u2019Connell","year":"2004","unstructured":"O\u2019Connell JB, Maggard MA, Ko CY (2004) Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 96:1420\u20131425","journal-title":"J Natl Cancer Inst"},{"key":"3888_CR4","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJM199002083220602","volume":"322","author":"CG Moertel","year":"1990","unstructured":"Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, Ungerleider JS, Emerson WA, Tormey DC, Glick JH, Veeder MH, Mailliard JA (1990) Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322:352\u2013358","journal-title":"N Engl J Med"},{"key":"3888_CR5","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1200\/JCO.1998.16.1.295","volume":"16","author":"MJ O\u2019Connell","year":"1998","unstructured":"O\u2019Connell MJ, Laurie JA, Kahn M et al (1998) Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 16:295\u2013300","journal-title":"J Clin Oncol"},{"key":"3888_CR6","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1056\/NEJMoa032709","volume":"350","author":"T Andre","year":"2004","unstructured":"Andre T, Boni C, Mounedji-Boudiaf L et al (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343\u20132351","journal-title":"N Engl J Med"},{"key":"3888_CR7","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1200\/JCO.2008.20.6771","volume":"27","author":"T Andre","year":"2009","unstructured":"Andre T, Boni C, Navarro M et al (2009) Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27:3109\u20133116","journal-title":"J Clin Oncol"},{"key":"3888_CR8","first-page":"1362","volume":"50","author":"S Sadahiro","year":"2003","unstructured":"Sadahiro S, Suzuki T, Ishikawa K, Nakamura T, Tanaka Y, Masuda T, Mukoyama S, Yasuda S, Tajima T, Makuuchi H, Murayama C (2003) Recurrence patterns after curative resection of colorectal cancer in patients followed for a minimum of ten years. Hepatogastroenterology 50:1362\u20131366","journal-title":"Hepatogastroenterology"},{"key":"3888_CR9","doi-asserted-by":"publisher","first-page":"8664","DOI":"10.1200\/JCO.2005.01.6071","volume":"23","author":"DJ Sargent","year":"2005","unstructured":"Sargent DJ, Wieand HS, Haller DG, Gray R, Benedetti JK, Buyse M, Labianca R, Seitz JF, O'Callaghan CJ, Francini G, Grothey A, O'Connell M, Catalano PJ, Blanke CD, Kerr D, Green E, Wolmark N, Andre T, Goldberg RM, de Gramont A (2005) Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 23:8664\u20138670","journal-title":"J Clin Oncol"},{"key":"3888_CR10","doi-asserted-by":"publisher","first-page":"3768","DOI":"10.1200\/JCO.2011.36.4539","volume":"29","author":"G Yothers","year":"2011","unstructured":"Yothers G, O\u2019Connell MJ, Allegra CJ et al (2011) Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol 29:3768\u20133774","journal-title":"J Clin Oncol"},{"key":"3888_CR11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1200\/JCO.2010.30.0855","volume":"29","author":"CJ Allegra","year":"2011","unstructured":"Allegra CJ, Yothers G, O\u2019Connell MJ et al (2011) Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: Results of NSABP protocol C-08. J Clin Oncol 29:11\u201316","journal-title":"J Clin Oncol"},{"key":"3888_CR12","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1001\/jama.2012.7265","volume":"307","author":"SR Alberts","year":"2012","unstructured":"Alberts SR, Sargent DJ, Nair S, Mahoney MR, Mooney M, Thibodeau SN, Smyrk TC, Sinicrope FA, Chan E, Gill S, Kahlenberg MS, Shields AF, Quesenberry JT, Webb TA, Farr GH Jr, Pockaj BA, Grothey A, Goldberg RM (2012) Effect of Oxaliplatin, Fluorouracil, and LeucovorinWith or Without Cetuximab on Survival Among Patients With Resected Stage III Colon Cancer. JAMA 307:1383\u20131393","journal-title":"JAMA"},{"key":"3888_CR13","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1200\/JCO.2012.44.4711","volume":"31","author":"CJ Allegra","year":"2013","unstructured":"Allegra CJ, Yothers G, O\u2019Connell MJ et al (2013) Bevacizumab in Stage II-III Colon Cancer: 5-Year Update of the National Surgical Adjuvant Breast and Bowel Project C-08 Trial. J Clin Oncol 31:359\u2013364","journal-title":"J Clin Oncol"},{"key":"3888_CR14","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1159\/000336902","volume":"84","author":"D Uncu","year":"2013","unstructured":"Uncu D, Aksoy S, \u00c7etin B, Yeti\u015fyi\u011fit T, \u00d6zdemir N, Berk V, Dane F, Inal A, Harputluo\u011flu H, Budako\u011flu B, Koca D, Sevin\u00e7 A, Cihan S, Durnal\u0131 AG, \u00d6zkan M, \u00d6zt\u00fcrk MA, I\u015f\u0131kdo\u011fan A, B\u00fcy\u00fckberber S, Benekli M, K\u00f6\u015f T, Alk\u0131\u015f N, Karaca H, Turhal NS, Zengin N, Anatolian Society of Medical Oncology (2013) Results of Adjuvant FOLFOX Regimens in Stage III Colorectal Cancer Patients: Retrospective Analysis of 667 Patients. Oncology 84:240\u2013245","journal-title":"Oncology"},{"key":"3888_CR15","doi-asserted-by":"publisher","first-page":"3385","DOI":"10.1200\/JCO.2009.21.9220","volume":"27","author":"CJ Allegra","year":"2009","unstructured":"Allegra CJ, Yothers G, O\u2019Connell MJ et al (2009) Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol 27:3385\u20133390","journal-title":"J Clin Oncol"},{"key":"3888_CR16","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1186\/s12885-015-1406-7","volume":"15","author":"D Pectasides","year":"2015","unstructured":"Pectasides D, Karavasilis V, Papaxoinis G et al (2015) Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer. BMC Cancer 15:384\u2013395","journal-title":"BMC Cancer"},{"key":"3888_CR17","first-page":"967","volume":"12","author":"\u015e Cihan","year":"2011","unstructured":"Cihan \u015e, Uncu D, Babacan NA, \u00d6zdemir N, Odaba\u015f H, Aksoy S, \u00d6ks\u00fczo\u011flu B, Zengin N (2011) Adjuvant modified FOLFOX-4 in patients with stage III rectum adenocarcinoma. Asian Pac J Cancer Prev 12:967\u2013970","journal-title":"Asian Pac J Cancer Prev"},{"key":"3888_CR18","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12885-015-1038-y","volume":"15","author":"SL Aspinall","year":"2015","unstructured":"Aspinall SL, Good CB, ZhaoX et al (2015) Adjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans. BMC Cancer 15:62","journal-title":"BMC Cancer"},{"key":"3888_CR19","doi-asserted-by":"publisher","first-page":"4868","DOI":"10.1002\/cncr.30950","volume":"123","author":"EM Cespedes Feliciano","year":"2017","unstructured":"Cespedes Feliciano EM, Lee VS, Prado CM, Meyerhardt JA, Alexeeff S, Kroenke CH, Xiao J, Castillo AL, Caan BJ (2017) Muscle mass at the time of diagnosis of nonmetastatic colon cancer and early discontinuation of chemotherapy, delays, and dose reductions on adjuvant FOLFOX: The C-SCANS study. Cancer 123:4868\u20134877","journal-title":"Cancer"},{"key":"3888_CR20","doi-asserted-by":"publisher","first-page":"196","DOI":"10.4174\/astr.2018.94.4.196","volume":"94","author":"D Park","year":"2018","unstructured":"Park D, Baek SJ, Kwak JM, Kim J, Kim SH (2018) Analysis of reduced-dose administration of oxaliplatin as adjuvant FOLFOX chemotherapy for colorectal cancer. Ann Surg Treat Res 94:196\u2013202","journal-title":"Ann Surg Treat Res"}],"container-title":["International Journal of Colorectal Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00384-021-03888-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00384-021-03888-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00384-021-03888-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T21:07:44Z","timestamp":1620940064000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00384-021-03888-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,14]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["3888"],"URL":"https:\/\/doi.org\/10.1007\/s00384-021-03888-9","relation":{},"ISSN":["0179-1958","1432-1262"],"issn-type":[{"value":"0179-1958","type":"print"},{"value":"1432-1262","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,14]]},"assertion":[{"value":"9 February 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the local Ethics Committee of Dicle University (Approval no: 147\/2019) and conducted in accordance with the Helsinki Declaration and ethical principles.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All authors have approved the manuscript and consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declared no potential conflicts of interest with respect to the research, authorship, and\/or publication of this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}